| Trial ID # | NCT02482311 |
| Phase | Ib |
| Drug Class | Cell Cycle Inhibitors: Wee1 |
| Drug Name | Adavosertib |
| Alternate Drug Names | WEE1 inhibitor AZD1775, MK1775, AZD1775 |
| Drugs in Trial | Adavosertib |
| Eligible Participant | Advanced solid tumors (with expansions in BRCA1/2 MUT ovarian cancer after PARPi-failure and BRCA WT ovarian cancer) |
| Patients Enrolled | 80 (30 BRCA1/2 MUT ovarian cancer after PARPi-failure, median 6 prior therapies; 16 BRCA WT ovarian cancer, median 7 prior therapies) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, PFS, evaluated per RECIST |
| Biomarkers | BRCA1/2 |
| Efficacy | Adavosertib (175 mg PO bid) on days 1–3 and 8–10 per 21-day cycle BRCA MUT after PARPi failure (n=30): BRCA WT (n=16): |
| Clinically Significant Adverse Events | Serious AE: 1 death |
| Conclusion | Adavosertib was well tolerated and showed preliminary antitumor activity. No clear correlation between genomic profile and clinical response was observed |
| Reference | Bauer TM et al. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Target Oncol (2023) 18(4):517-530 |